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ABSTRACT 
 
Cells of multicellular organisms are genetically homogenous but are heterogeneous in 
terms of morphology and functional specialization as a consequence of cell-specific expression 
of various sets of genes. During development, this cellular differentiation is established, 
maintained and changed in conjunction with cascades of transcription factors and epigenetic 
modulators such as DNA methylation, histone modifications, non-coding RNAs which work in 
tandem to co-ordinate the activity and regulation of the genome. DNA methylation is the 
principle epigenetic signal inducing genetic variation and plays a quintessential role in control of 
gene expression, cellular differentiation and development, preservation of chromosomal 
integrity, parental imprinting and X-chromosome inactivation. DNMT1, the maintenance 
methyltransferase is the main perpetuator of methylation, faithfully propagating existing methyl 
marks across successive cell divisions. Several intrinsic and extrinsic mechanisms in the 
mammalian cells regulate DNMT1 levels, their activity and stability including varied 
transcriptional activation of the respective genes, post-translational modifications of the enzyme, 
numerous interactions with other molecules involved in DNA methylation can affect catalytic 
activity, targeting and enzyme degradation at multiple levels . A comprehensive knowledge 
about DNMT1, its structural and functional organization, regulatory mechanisms and 
quantification of the various interactions is essential to elucidate its function at the molecular 
level and to understand the dynamics of DNA methylation at the cellular level. The present study 
was carried out to clone and characterize DNMT1. Further structure-function studies in this area 
will provide a comprehensive idea on DNMT1 function. 
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         i 
1 
 
      INTRODUCTION 
 
Epigenetically mediated changes in gene expression are being increasingly appreciated. 
This process involves two components of heritable and reversible modulation of gene promoter 
function that are closely tied to one another – formation of chromatin which modulates 
transcription and establishing patterns of DNA methylation (Rountree et al., 2001). DNA 
methylation includes covalent addition of a methyl group to cytosine inside the CpG dinucleotide 
forming methyl cytosine. DNA methyltransferase catalyzes this reaction in the context of the 
sequence 5’-CG-3’, referred to as a CpG dinucleotide. It is the most frequent eukaryotic DNA 
modification and is one of the many epigenetic (alteration in gene expression without a change in 
nucleotide sequence) phenomena (Singal and Ginder, 1999). Today epigenetic inheritance can be 
defined as cellular information or the information encoded in the genome, other than the DNA 
sequence itself that is heritable during cell division thus representing a critical mechanism that 
allows a remarkably stable propagation of gene activity states over many cell generations 
(Feinberg and Tycko, 2004).  
Epigenetic mechanisms are versatile and adapted for specific cellular memory function 
not only during development but throughout the life-time. The effects of DNA methylation 
comprise of control of gene expression by transcriptional repression via inhibition of 
transcription factor binding or recruitment of methyl binding protein and the chromatin 
remodeling factors associated with them, X-chromosome inactivation, parental imprinting and 
the suppression of parasitic DNA sequences. DNA methylation is also essential for the proper 
embryonic development of organisms (Robertson and Jones, 2000). It has been implicated in 
brain function and the development of the immune system. These diverse processes appear to 
share a common characteristic i.e., they all exert a stabilizing effect promoting the genomic 
integrity and ensuring accurate temporal and spatial gene expression during development.  
Genomic DNA methylation patterns are discrete regions and are not randomly 
distributed. Most repetitive and parasitic DNA is hypermethylated whereas, CpG - rich regions 
(CpG islands) coupled with the regulatory regions of genes are hypomethylated (Yoder et al., 
1997). Moreover, DNA methylation patterns change significantly during the development of 
embryo. Widespread demethylation in the genome after fertilization is followed by waves of     
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de novo methylation after embryonic implantation. This emphasizes on the regional specificity 
of genomic DNA methylation patterning (Reik et al., 2001). DNA methylation and DNA 
demethylation are two sides of the same coin, representing two opposing yet concerted 
mechanisms forming the basis of epigenetic regulation of genome. The demethylation 
mechanisms, the candidate enzyme(s) that exhibit direct demethylase activity, and coupled 
cofactors are not firmly established. In recent studies the methyl-binding domain proteins MBD2 
and MBD4 have been shown to have possible demethylase activity, but concrete supporting 
evidences concerning this hypothesis has not yet been proved (Bird, 2002).  
DNA methylation and the `tightness' of packaging of the DNA in nucleosomes and the 
higher order structures they form are physically and functionally linked to each other (Bird, 
2002). All known catalytically active DNA methyltransferases interact with histone deacetylases 
and effect of inhibitors on each of these processes revealed their interplay to repress transcription 
(Cameron et al., 1999).  
Changes in DNA methylation pattern play vital role in the development of cancer. The 
accurate genomic methylation pattern is essential for healthy cells. If methylation patterns are not 
appropriately established or maintained, disorders such as mental retardation, immune deficiency 
and sporadic cancers may occur. In tumor cells, the normal regulation of the DNA methylation 
machinery is severely disrupted, resulting in reversal of the regional specificity of methylation 
patterns, leading to de novo methylation of CpG islands and hypomethylation of repetitive DNA 
(Baylin et al., 2001).  
Epigenetics is a new frontier in research with remarkable impact on our thinking and 
understanding of biological phenomena and complex diseases. Over the past decade there has 
been significant progress in our knowledge of the importance of epigenetic events in the control 
of both normal cellular processes and abnormal events associated with tumor development and 
progression. DNA methylation is a key epigenetic mechanism most intensively studied in the 
context of gene regulation and silencing in cancer cells. 
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                Fig.1. Possible epigenetic modifications (Jane, Nature 2006)  
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  REVIEW OF LITERATURE  
 
DNA METHYLATION: 
DNA methylation is one of the covalent modifications of nucleotides and in the human 
genome the most frequently methylated nucleotide is a cytosine which is followed by N6 
position of guanine, giving rise to a CpG dinucleotide. The methylation of cytosine occurs in the 
C-5 position by a family of DNA (cytosine-5) methyltransferases (DNMTs) which transfers the 
methyl group from the universal methyl donor S-adenosyl- L-methionine (SAM / AdoMet) 
(Luczak and Jagodzinski, 2006). The methyl groups are positioned in the major groove of the 
DNA, where they do not interfere with the Watson/Crick base-pairing capacities of the 
nucleotides (Hermann et al., 2004). 
 
                                       
 
 
                     Fig.2. Methylation of cytosine by DNMTs  
                            (Adapted from Walsh and Xu, Curr Top Microbiol Immunol, 2006) 
 
 
Eukaryotic genomes are not uniformly methylated rather they contain methylated 
domains interspersed with unmethylated domains (Bird, 1986). Small portions of DNA called 
CpG islands, whose size ranges from 0.5 to 5 kb and occurs on average of every 100 kb, have 
distinctive properties in contrast to the remaining portion of the genome. These islands are GC 
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rich (60% to 70%) having CpG to GpC in ratio of at least 0.6, usually associated with the 
promoter i.e., the 5'-end of almost all genes, they are also unmethylated and thus do not show 
repression in the frequency of the dinucleotide CpG (Cross and Bird, 1995).With evolution, the 
dinucleotide CpG has been gradually eliminated from higher eukaryotic genome and is present at 
only 5% to 10% of its predicted frequency.10-12 Cytosine methylation plays a major role in this 
process, because most of the CpG islands lost are due to deamination of methylcytosines to 
thymines. 70% to 80% of the remaining CpG sites contain methylated cytosines in majority of 
vertebrates, including humans (Antequera and Bird, 1993; Bird, 1995). These methylated regions 
are characteristic of the bulk chromatin representing the replicating DNA with its histone 
composition and nucleosomal configuration and is comparatively unapproachable to 
transcription factors. It is anticipated that there are 45000 CpG islands in the genome of humans 
associated with nearly half of all genes (Antequera and Bird, 1993). Housekeeping genes usually 
contain CpG islands and have a broad pattern of expression.  
 
 
              
   
                             Fig.3: The –CpG– dinucleotide of DNA  
                  (Adapted from Patra et al., Cancer Metast Rev. 2008) 
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DNA METHYLTRANSFERASES (DNMTS): 
 
DNA methyltransferases (DNMTs) are responsible for both establishing as well as 
maintaining the DNA methylation pattern of cells. Till date four catalytically active DNMTs are 
known in mammals: DNMT1, DNMT2, DNMT3A, and DNMT3B. They are classified into two 
types, maintenance and de novo methyltransferases. The enzyme DNMT1 is responsible for 
maintenance methylation and hence known as maintenance methyltransferase. DNMT1 binds 
methyl groups to the hemimethylated regions of DNA during replication. The enzyme DNMT3A 
and DNMT3B are linked to de novo methylation and hence called de novo methyltransferases. 
They add methyl groups to CpG dinucleotides of unmethylated regions of DNA. 
 
 
 
     
      Fig.4. Maintenance and de novo DNMTs methylating DNA 
 (Adapted from Patrick et al., Elsevier 2010) 
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DNMT1 
The (cytosine-5) DNA methyltransferase 1, i.e. DNMT1 was the first mammalian DNA 
methyltransferase to be isolated. The gene encoded for DNMT1 is present in chromosome 19 
localized at 19p13.2 in human (Yen et al., 1992). The DNMT1 gene in human spans more than 
60kb in the genome, composing at least 40 exons and 39 introns, and its canonical single 
transcript spreads about 5.2 kb long (Ramchandani et al., 1998). The protein DNMT1 is 
predominantly expressed in somatic tissues and proliferating cells, and contains 1616 amino acid 
residues with molecular mass of about 190 kDa (Leonhardt and Bestor, 1993). DNMT1 has 
specificity for hemimethylated double-stranded DNA as compared to unmethylated double-
stranded DNA. This unique property of DNMT1 gives it the name of “Maintenance DNA 
methyltransferase” (Pradhan et al., 1999; Yokochi and Robertson, 2002). Whereas DNMT1 is 
localized at replication foci during S-phase, it is actively excluded from the nucleus in fertilized 
eggs and stored in the cytoplasm, leading to so called passive demethylation of the female 
genome that occurs because DNA replication is not accompanied by DNA methylation during 
the first DNA replication cycles of fertilized eggs (Chuang et al., 1996). 
 
STRUCTURAL ORGANIZATION OF DNMT1: 
DNMT1 comprises a large N-terminal domain with regulatory function and a smaller C-
terminal catalytic domain (Bestor, 2000).  
 
Regulatory Domain of DNMT1: The regulatory domain (about 1,100 amino acid residues) 
harbors different motifs- 
 A Charge-rich domain interacts with the DNMT1-associated protein (DMAP1), a 
transcriptional repressor and contains different start codons 
 A nuclear localization signal (NLS) induces DNMT1 importing into nucleus (Bestor and 
Verdine , 1994) 
 A proliferating cell nuclear antigen (PCNA) binding domain is associated with 
replication during S phase (Chuang et al., 1997) 
 A replication foci targeting region (RFT / TS) is considered to target DNMT1 towards 
DNA in S phase during cell cycle (Leonhardt et al., 1992) 
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 A cysteine-rich Zn2+ binding domain of the CXXC type. The zinc domain comprises 
eight conserved cysteine residues in two CXXCXXC clusters and two isolated cysteines 
(Rountree et al., 2000). 
 One part of the N-terminal domain shows homology to the Polybromo-1 protein from 
chicken; this domain contains two BAH (Bromo-adjacent homology) domains that may 
be involved in protein-protein interaction. The Polybromo-1 protein mediates 
interactions of different chromatin components. The DNMT1 polybromo domain is 
supposed to play a role in the transport of DNMT1 to the replication foci as well (Liu et 
al., 1998). The BAH1 and BAH2 domains act as protein-protein interaction modular 
motifs (Callebaut et al., 1999). The BAH domain has an elongated shape comprising 
mainly antiparallel β-strands and a small helical domain (Zhang et al., 2002). The         
N-terminal part of DNMT1 is involved in the intracellular delivery and regulation of 
catalytic activity of DNMT1.  
 
The C- and N-termini are connected via a lysine-glycine (GK) repeat hinge region (Pradhan et 
al., 1997).  
 
Catalytic Region of DNMT1: The C-terminal catalytic region in DNMT1 contains ten 
characteristic sequence motifs (i.e. conserved motifs I–X), and the spacing sequences between 
each conserved motifs is referred as variable regions. Several lines of evidence further indicate 
that about six of the conserved motifs, that is motifs I, IV, VI, VIII, IX, and X, might be highly 
conserved in mammalian DNMTs. C-terminal catalytic region of DNMT1 could be oriented and 
folded into two domains. The large and small domains were separated by a large cleft         
(Kumar et al., 1994).  
 
 Large Domain: The distribution of motifs arranged in the two domains is extremely 
asymmetric. The large domain encompasses the most conserved motifs, including motifs 
I–VIII and the most C-terminal part of motif X, which could be participated in Ado-Met 
[S-adenosyl-L-methionine (SAM)] cofactor binding, substrate (cytosine) targeting, and 
essential catalysis events. The “core” structure in the large domain is composed of the 
highly conserved motifs I, IV, VI, and VIII. Most of the constant amino acid residues, in 
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the “core” structure such as PC dipeptidyl residues (proline-cysteine) in motif IV 
constituting the catalytic loop, are indicated to be situated facing the cleft and to be 
clustered around the active site in the C-terminal region of the DNMT1 molecule       
(Kumar et al., 1994). 
 
 Small Domain: The small domain comprises an extremely long variable region between 
conserved motif VIII and IX, conserved motif IX and partial N-terminal region of 
conserved motif X (Kumar et al., 1994). 
 
The catalytic domain of DNMT1 alone is not sufficient for the enzymatic activity                 
(Fatemi et al., 2001). Enzyme activity was only observed in the presence of a substantial part of 
the N-terminal region (Margot et al., 2000). Most likely through intramolecular interaction of 
these domains, a conformational change of the catalytic domain of DNMT1 into an active 
conformation is induced (Pradhan and Esteve, 2003). 
 
 
DNMT1 VARIANTS: 
 DNMT1 has different translational start points, and exists in different splice variants 
(Mertineit et al., 1998). The predominant splicing isoform in somatic cells in human comprises 
1616 amino acid residues. A shorter germ-cell-specific form of DNMT1 called DNMT1o is 
found in growing oocytes and during pre-implantation development. DNMT1o lacks the           
N-terminal 114 amino acid residues and displays an increased stability in vivo against 
degradation (Ding and Chaillet, 2002). The intrinsic stability of the DNMT1o protein allows 
creating stable ooplasmic stores of DNMT1o that are available in the nuclei of the eight-cell-
stage embryo and maintain methylation patterns on alleles of imprinted genes during the fourth 
embryonic S-phase (Ratnam et al., 2002). Another splice form of DNMT1 is DNMT1b, which 
incorporates in frame an additional 48 nt between exons 4 and 5. The amount of DNMT1b 
protein in somatic cells is only 2–5% the level of the known DNMT1 and its enzymatic 
properties are similar but the biological functions of DNMT1b are not clear at present (Bonfils et 
al., 2000). 
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                   Fig.5. The architecture of DNMT1 (human: 1616 aa) and its splicing isoforms 
                                            (Adapted from Hermann et al., CMLS 2004) 
 
(Charge-rich region: contains several translation start points; PCNA: PCNA-interaction site; 
NLS: nuclear localization signal; P: major phosphorylation site at Ser 514, Cys-rich-region: 
cysteine-rich zinc binding motif; Pb-region: polybromo-1 protein homologous region containing 
two BAH domains; GK-repeats: glycine-lysine-repeats). 
 
DNMT3A 
The DNMT3A gene in human is mapped down to chromosome 2p23 (Robertson et al., 
1999) and showing almost 96% amino acid identity to its murine counter part (Xie et al., 1999). 
The carboxy terminus of DNMT3A comprises of highly conserved catalytic motifs. DNMT3A is 
enzymatically active in both in vitro and in vivo conditions, although there is difference in the 
exact substrate preference of DNMT3A (Gowher and Jeltsch, 2001; Yokochi and Robertson, 
2002). DNMT3 family usually has a cysteine-rich portion in the amino terminal region, referred 
to as PHD (plant homeo domain) or ATRX like domain, due to its homology with the PHD 
portion of the ATRX gene. ATRX is one of the members of the SNF2/SWI2 family of the ATP-
dependent chromatin remodeling complexes. This resemblance suggests that DNMT3A is 
associated with the structural changes in chromatin by means of interactions between various 
proteins at the amino terminal region. DNMT3A transcripts are universally expressed in adult 
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tissues, most tumor cell lines, all early embryos and the embryonic stem (ES) cells (Robertson et 
al., 1999; Xie et al., 1999). 
 
 
  
     Fig.6. Structure of DNMT 3A (Adapted from Hermann et al., CMLS 2004) 
 
DNMT3B 
The DNMT3B gene in human is mapped down to the 20q11.2 chromosome (Robertson et 
al., 1999; Xie et al., 1999) and it has 85% identity with murine DNMT3B. The catalytic domain 
is located at the carboxy terminus which is well conserved between DNMT3A and DNMT3B 
(more than 80% identity), while their amino terminal regions are poorly conserved (less than 
30%). DNMT3B is also an active DNA methyltransferase both in vivo as well as in vitro (Okano 
et al., 1999). The levels of expression of DNMT3B as compared to DNMT3A are very low in 
most tissues. However, DNMT3B is expressed in greater degrees in the testes, which suggests a 
vital role of DNMT3B in spermatogenesis (Okano et al., 1998; Robertson et al., 1999; Xie et al., 
1999). Unlike DNMT3A, there are several isoforms (five for human and eight for mouse) of 
DNMT3B resulting from alternative splicing. Three major isoforms - DNMT3B1, DNMT3B2, 
and DNMT3B3 are identified (Okano et al., 1998) which are tissue specifically expressed 
(Robertson et al., 1999). 
 
 
                   Fig.7. Structure of DNMT 3B (Adapted from Hermann et al., CMLS 2004) 
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Mechanism of DNA Methylation:       
 
 
This catalytic process involves a nucleophilic attack of the enzyme on the C6 of the target 
cytosine. The attack is performed by the thiol group of the cysteine residue in a PCQ motif 
conserved in the active site of cytosine-C5-MTases (motif IV). The formation of the covalent 
bond activates the C5 atom towards electrophilic attack and leads to the addition of the methyl 
group from AdoMet to C5 of the cytosine followed by elimination of the 5-position proton and 
resolution of the covalent intermediate. The glutamic acid of the amino acid motif ENV (motif 
VI) is important to stabilize the DNA-protein complex. The methyl group of AdoMet is bound to 
a sulphonium atom, which thermodynamically destabilizes the molecule and makes the relatively 
inert methyl thiol of the methionine moiety very reactive towards nucleophilic attack by 
activated C atom (carbanion) of Cytosine (Hermann et al., 2004). 
      
 
                 
 
                                     Fig.8. General DNA (cytosine-C5) methylation reaction  
                                        (Adapted from Patra et al., Cancer Metast Rev. 2008) 
13 
 
 
 
 
                                Fig.9. Catalytic mechanism of DNA (cytosine-C5) methylation 
              (Hermann et al., CMLS 2004; Reither et al., Journal of Molecular Biology 2003) 
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Table-1: DNA methyltransferase-associated proteins involved in transcriptional repression and 
chromatin modification (Robertson, 2002)   
 
DNA methyl-
transferase 
Interacting 
Protein 
Function of interacting 
protein 
How do they work together? 
DNMT1 HDAC1/2 Histone deacetylase Modification of chromatin by histone 
deacetylation, targeting methylation? 
 pRb Tumor suppressor 
Cell-cycle regulation 
Sequester DNMT1 in non-dividing cell, 
target or modulate DNMT activity at 
replication foci? 
 DMAP1 Co-repressor Recruiting other repressors, 
transcriptional repression 
 PML-RAR Oncogenic transcription 
factor 
DNA- binding and interaction with other 
transcriptional co-regulators, targeting 
methylation 
 MBD2/3 Methyl-CpG binding 
proteins 
Transcriptional repression in methylated 
regions, possible targeting of DNMT1 to 
hemi-methylated DNA at replication foci? 
DNMT3A HDAC1 Histone deacetylase Modification of chromatin by histone 
deacetylation, targeting methylation? 
 RP58 transcription factor Sequence- specific DNA binding, 
targeting repression, may be methylation 
as well? 
 PML-RAR Oncogenic transcription 
factor 
DNA- binding and interaction with other 
transcriptional co-regulators, targeting 
methylation 
DNMT3B HDAC1 Histone deacetylase Modification of chromatin by histone 
deacetylation, targeting methylation? 
 SUMO-1/Ubc9 Sumo ligase Modification of protein by sumoylation, 
altered localization or enzymatic activity? 
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FUNCTIONS OF METHYLATION 
 
Cytosine methylation has various functions. Methylation within the regulatory elements of a 
gene such as promoters, enhancers, insulators, and repressors usually suppresses its function. 
Imprinted genes and those present on the inactive X-chromosome are the prominent examples of 
transcriptional repression caused by methylation. Methylations within the gene deficient regions 
including pericentromeric heterochromatin are crucial for the maintenance of conformation and 
integrity of the chromosome (Ehrlich, 2002). Methylation has also been proposed as a genomic 
defense against mobile genetic elements like transposons (Bestor, 1999). 
 
1. DNA methylation in transcriptional repression: 
 
Methylation blocks transcription by two mechanisms (Nan et al, 1998). First, binding of 
certain transcription factors to their CpG containing recognition sites are inhibited by 
methylation (Tate and Bird, 1993). Second mechanism involves protein complexes - MeCP2 or 
MeCP1, binding specifically to the methylated CpGs and thereby indirectly inhibiting the 
binding of transcription factors to the DNA by reducing their access to the regulatory element 
(Nan et al, 1998; Hendrich and Bird, 2000). Various DNMT- associated proteins involved in 
transcriptional repression are noted in Table 1. 
 
2. X- chromosome inactivation: 
 
Inactivation of one of the two X- chromosomes in female cells during development occurs by 
a methylation dependent process (Goto and Monk, 1998). CpG islands contain promoters of 
majority of genes on the inactive X- chromosome, including various housekeeping genes such as 
HPRT, G6PD and PGK1, which are methylated and are transcriptionally silent, apparently to 
ensure equivalent expression levels in both male and female cells (Kass et al, 1997). Silencing 
precedes methylation in many of these genes (Jaenisch et al, 1998) and thus serves to maintain 
silencing and does not initiate the event. The XIST (X- inactive specific transcript) gene 
expression is also associated with the methylation status of its promoter. It is unmethylated and 
expressed in case of the inactive X while it is methylated and silent on the active X. Embryonic 
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stem cells from which DNMT1 is deleted, expresses the usually silenced XIST gene on the 
active X chromosome in males (Goto and Monk, 1998). 
 
 
3. Gene imprinting: 
 
Methylation is also essential for the imprinted genes to express. Majority of the genes are 
expressed from both maternal and paternal alleles, while a noticeable number of “imprinted” 
genes are expressed in an origin specific manner (Tycko, 1997). Gene imprinting involves allele 
specific methylation in the CpG- islands related to these genes, through mechanisms not fully 
understood (Bartolomei, 1993; Tremblay et al, 1995). 
 
 
DNA METHYLATION AND CANCER 
 
The cancer cells unlike normal cells show major disruptions in DNA methylation patterns 
(Baylin and Herman, 2000). Changes in the genome wide methylation level (global 
hypomethylation) as well as the methylation patterns of particular genes (gene specific 
hypermethylation) are characteristic for the various types of cancer cells. Influence of DNA 
methylation on cancer involves the two following mechanisms: 
 
(1) Global hypomethylation 
(2) Gene specific hypermethylation 
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                              Fig.10. Effects of hypomethylation and hypermethylation  
                                  (Takai and Jones, Proc Natl Acad Sci U S A., 2002) 
 
1) DNA hypomethylation: 
 
Hypomethylation is pragmatic in a variety of malignancies (Feinberg and Voglstein, 1983; 
Kim et al, 1994). It is commonly seen in solid tumors including metastatic hepatocellular cancer, 
cervical cancer, prostate cancer as well as hematologic malignancies like B-cell chronic 
lymphocytic leukemia (Ehrlich, 2002).  
Global hypomethylation is seen in a number of cancers, such as breast, cervical and brain, 
showing a progressive increase in proficiency of malignancy (Ehrlich, 2002). The regions of 
pericentric heterochromatin on chromosomes 1 and 16 are profoundly hypomethylated in 
immunodeficient patients, in cases of centromeric instability and facial abnormalities also in 
various cancers. In patients with ICF i.e., immunodeficiency, centromeric instability and 
abnormalities of face, a mutation of DNMT3b is seen, causing the instability of the chromatin 
(Okano et al, 1999). Hypomethylation leads to oncogenesis by activating the oncogenes or by 
activating the dormant retrotransposons (Alves et al, 1996), or by instability of chromosome. 
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 Retrotransposon activation 
 
DNA methylation usually suppresses the expression of retrotransposons. Hypomethylation 
and subsequent expression of these mobile elements has been observed in human cancer (Florl et 
al., 1999). This leads to movement of the retrotransposons and their reintegration at new sites in 
the genome, giving rise to insertional mutagenesis observed in cancer, but they are not quite 
frequent (Miki et al., 1992). LINE (Long Interspersed Nuclear Element 1, a 6-kb interspersed 
DNA repeat which makes up around 15% of the human genome) hypomethylation occurs early 
in cancer initiation, notably in cancers of the colon and prostate (Wilson et al., 2007). 
 
 Chromosome instability 
 
Chromosomal aberrations are generally observed in cancer and DNA methylation is involved 
in the control of chromosome stability. It is seen that patients having the autosomal recessive ICF 
(immunodeficiency, instability in centromere and anomalies of face) syndrome (Szyf, 2003), 
caused by the mutation of DNMT3B, leads to demethylation and exhibit instability of the 
pericentric heterochromatin regions on chromosomes 1, 9 and 16 (Wilson et al., 2007). 
Instability due to hypomethylation of these portions on chromosomes 1 and 16 are also observed 
in the ovarian, breast and Wilms’ tumors (Narayan et al., 1998). Global hypomethylation causes 
a global change in chromatin structure by promoting chromosomal instability, a hallmark of 
cancer (Szyf, 2003). 
 
 Oncogene activation 
 
Hypomethylation of DNA plays a significant role in activation of certain genes, particularly 
oncogenes. Various genes mapped to the X-chromosome show demethylation in their promoter 
regions leading to activation causing tumor (Vachtenheim et al, 1994). There is report  of 
hypomethylation of  c-myc  and  Ha-ras  oncogenes in human tumor samples from colonic 
adenocarcinoma and small cell lung carcinoma relative to adjacent normal tissue as well as other 
oncogenes (Patra and Bettuzzi, 2009). 
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        Fig.11. Potential causes and subsequent consequences of DNA hypomethylation in cancer 
                                 (Wilson et al., Biochimica et Biophysica Acta 2007) 
 
 
2) DNA hypermethylation 
 
Global hypomethylation of the genome is exhibited by tumor cells accompanied by region-
specific hypermethylation events (Baylin and Herman, 2000). It is anticipated that the ancestral 
role of DNA methylation was to restrain the spreading of parasitic elements with the increase in 
size and complexity of the genomes and the increasing dangers to genome integrity from 
unrestrained transposition events (Yoder et al., 1997). This defense system of genome is utilized 
as a means of gene regulation. CpG islands are frequent targets of hypermethylation events. 
Methylation of CpG islands is rare in normal cells. It plays vital role in X-chromosome 
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inactivation in females as well as genomic imprinting. It also increases with age and in vitro cell 
culture. Anomalous methylation of CpG islands efficiently repress transcription of the allied 
genes by certain processes similar to mutation and deletion mechanisms thereby acting as the 
first `hit' in the Knudsen’s two-hit hypothesis for generation of tumor (Baylin and Herman, 
2000). There are numerous examples of hypermethylation of promoter region in the aberrant 
CpG islands of the tumor suppressor genes, genes which are involved in cell-cell adhesion and 
genes which are involved in DNA repair. 
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OBJECTIVE OF THE PROJECT 
 
The main aim is to observe the expression levels of the DNMT 1 gene in the normal cells 
and comparing the results with the cancer tissues. It is required to study the expression of the 
DNMT1 enzyme, as it  is  having  a  major  role  in  the  maintenance  of  the  genomic  
methylation  and  also  the transcriptional regulatory changes in the human cancer, in order to 
clearly understand its role in cancer development. Further research has to be carried out to 
characterize its functions and to  clarify  the  role  of  the  DNMT1  in  the  aberrant  
hypermethylation  and hypomethylation in various human cancers. Cloning will help in 
producing the enzyme in large quantity and thereby can be used to further study its effects in 
functioning as well as malfunctioning of cells. 
Our main objective was ― Cloning of DNA methyltransferase 1 (DNMT1) gene from a normal 
cell. 
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                          MATERIALS AND METHODS 
 
 
1. Collection of Sample: 
Normal human blood was collected from the local CWS Hospital, Rourkela, Odisha, stored 
in ice and immediately processed for better genomic DNA extraction. 
   
 2. In silico Sequence Analysis of DNMT1 gene: 
   The cDNA sequence and protein sequences of DNMT1 gene were retrieved from NCBI 
database at http://www.ncbi.nlm.nih.gov and EMBL database at http://www.ebi.ac.uk/embl/. 
 
3. Extraction of RNA from Blood by RNA Purification Kit (Fermentas): 
The collected blood was centrifuged at 3000 rpm for 15 min at 4°C. The supernatant 
containing the serum was separated from the pellet containing the blood cells. The pellet was re-
suspended in 600 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-mercaptoethanol for 
every 1ml of Lysis Buffer) and vortexed well to mix thoroughly. 450 μl of ethanol (96-100%) 
was added to the solution. About 700 μl of the lysate was transferred to a GeneJETTM RNA 
Purification Column inserted in a collection tube and centrifuged at 12000 rpm for 1 min at 4°C. 
The flow-through was discarded and the column was placed into a new RNase-free 
microcentrifuge tube. 700 μl of Wash Buffer 1 was added (supplemented with 250 μl of ethanol 
for every 1ml Wash buffer 1) to the column and centrifuged for 1 min at 12000 rpm. The flow-
through was discarded and 600 μl of Wash Buffer 2 was added (supplemented with 850 μl of 
ethanol for every 0.5 μl Wash buffer 2) to the column. It was centrifuged at 12000 rpm for 1 min 
at 4°C. The flow-through was again discarded. Centrifugation was again done at 12000 rpm for  
1 min at 4 °C by adding 250 μl of Wash buffer 2. The flow-through was discarded and the 
column was transferred to a sterile 1.5 RNase-free microcentrifuge tube. 100 μl of nuclease-free 
water was added to the column and centrifuged for 1 min at 12000 rpm to elute RNA. The RNA 
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was immediately used for cDNA synthesis after determining the concentration of the isolated 
RNA by Nanodrop.  
 
5. First strand cDNA synthesis: 
Total RNA (4 g) was used for first strand cDNA synthesis by reverse transcription using 
RevertAid
TM 
first Strand cDNA Synthesis Kit (Fermentas) in a thermal cycler (Biorad). The 
RNA was incubated with 1 l of oligo (dT) primers (100 μM, 0.2 μg/μl) and 12 μl of nuclease-
free water at 65 C for 5 min. The reaction was cooled on ice to allow the primers to anneal to 
the RNA, spun down and kept in ice again. Then 4 l of 5X Reaction Buffer, 1 l of RibolockTM 
RNase inhibitor (20 U/l), 2 l of 10 mM dNTPs and 1.0 L of RevertAidTM M-MuLV-Reverse 
Transcriptase (200 U/l) were added in sequence, gently mixed and incubated for 1 hr at 42C. 
The reaction was terminated by heating at 70C for 5 min and the synthesized cDNA was further 
used for DNMT1 gene amplification by gene specific PCR. 
 
6. Gene-specific PCR Amplification of DNMT1: 
A set of specific forward and reverse primers were designed using the Perlprimer 
software. The isolated genomic DNA was used as the template to amplify the DNMT1 gene 
through PCR using the specific primers. 
A master mix was prepared in a sterilized eppendorf  tube by adding 40.8µl of autoclaved 
Millipore water, 5µl of 10xTaq assay buffer,1 µl forward primer,1 µl reverse primer, 1 µl dNTPs 
and 0.2 µl of Taq DNA  polymerase. Then it was mixed properly by short spin and kept it in ice. 
1 µl cDNA was taken and was put into the PCR tube. The tube was tapped gently and spun for 
few seconds. After this the tube was placed in thermal cycler with program set as follows: 94
°
C 
for 1 min (Initial denaturation), 94
0
c for 20 sec (Denaturation), 58
0
c for 20 sec (Annealing), 72
0 
C
 
for 30 sec (Extension) and 72
0
c for 5 min (Final extension). Finally was held for 1 min at 4 
°
C.  
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7. Gel Elution 
        The PCR product (amplified DNMT1 gene) was gel eluted and then purified using SIGMA 
GenElute™ Gel Extraction Kit. All centrifugations were performed at 12,000 to 16,000 x g. The 
DNMT1 band was excised from the agarose gel with a clean, sharp scalpel or razor blade. Excess 
gel was trimmed away to minimize the amount of agarose. The gel was then weighed in a tared 
colorless tube. 3 gel volumes of the Gel Solubilization Solution was added to the gel slice. The 
gel mixture was incubated at 50-60 °C until the gel slice completely dissolved.  It was vortexed 
briefly every 2-3 minutes during incubation to help dissolve the gel. The Gen Elute Binding 
Column G was placed into one of the provided 2 ml collection tubes. 500 mL of the Column 
Preparation Solution was added to the binding column. Then it was centrifuged for 1 minute. 
Flow-through liquid was discarded. 1 gel volume of 100% isopropanol was added and mixed 
until homogenous. The solubilized gel solution mixture was loaded into the binding column. 
After loading the column each time it was centrifuged for 1 minute. The flow-through liquid was 
discarded. 700 mL of Wash Solution was added to the binding column and Centrifuged for 1 
minute. The binding column was removed from the collection tube and the flow-through liquid 
was discarded.  The binding column was placed back into the collection tube and centrifuged 
again for 1 minute without any additional wash solution in order to remove excess ethanol. The 
binding column was transferred to a fresh collection tube and 50 mL of Elution Solution was 
added to the center of the membrane and incubated for 1 minute.  Then it was centrifuged for 1 
minute.  For efficient recovery of intact plasmid DNA, the elution solution was preheated to     
65 °C prior to adding it to the membrane. 
 
8. Preparation of ligation mixture 
Before use ligation buffer was vortexed properly and then short spinned. 5µl of ligation 
mixture was prepared  in a sterilize eppendorf  tube by adding  2.5 µl of ligation buffer,1.5µl of 
PCR product (Insert), 0.5 µl of  DNA ligase and 0.5 µl of pBSK(-) vector (PROMEGA). The 
reaction mixture was mixed properly by pipetting and was incubated over night at 4
0
c 
temperature. 
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             Fig.12. The pBSK (-) vector used for ligation and transformation 
 
 
 
MCS 
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9. Transformation 
 
1) Competent cell preparation: 
E.coli which is present in glycerol stock solution cannot be taken directly because here the 
cell is present in stationary phage. So they are first made competent. 
 First  200 µl  of  DH5α  strain of  E.coli  was taken in a eppendorf  tube containing  2ml  LB. 
The culture was then incubated over night at 37
0
C in water bath shaker to bring the bacteria to 
their log phase. From this culture 300 µl of DH5α stain was taken in an eppendorf tube 
containing 100 ml of LB media. Then the tubes were incubated at 37
0
 C temperature in water 
bath shaker .When  growth was observed  after 2 hr then 12ml of culture was taken in 15ml of 
tarson tube and immediately placed into ice box. Then the tube was centrifuged at 5000 RPM for 
5 min at 4
0
C temperature, supernatant was discarded. The pellets were dissolved into 500µl of 
0.1 µl Cacl2. This solution was then transferred into new eppendorf tube and incubated in ice. 
After that the tube was centrifuged at 5000 RPM for 5 min at 4
0
 C and supernatant was 
discarded. The pellets were dissolved into 100 µl of 0.1M CaCl2 and incubated for 15 min into 
ice. 
2) Insertion of vector to competent cell: 
For the insertion of vector to competent cell exactly 100 µl of competent cell and 5 µl of 
ligation mixture were taken in a sterilized eppendorf tube. Then the tube was immediately 
incubated in ice for 1hr. A brief heat shock was given at 42
0
c exactly for 90 sec. and immediately 
chilling in ice for 15 minutes. Then the contents were transferred into tarson tube containing 
1.5ml-2ml LB media. After that the contents were incubated over night at 37
0
c in water bath 
shaker. 
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10. Blue white colony selection 
 
The blue-white screen is a molecular technique that detects successful ligations in vector-
based gene clonings. DNMT1 was ligated into the pBSK (-) vector. The vector was then 
transformed into competent E.coli cells. The competent cells were grown in the presence of X-
gal. Successful ligation and transformation gives rise to white bacterial colonies instead of blue. 
This technique allows for the quick and easy detection of successful ligation. 
The molecular mechanism for blue-white screening is based on genetic engineering of the 
lac operon. The vector pBSK (-) encodes the α subunit of LacZ protein with an internal, while 
the chromosome of the host strain encodes the remaining ω subunit to form a functional β-
galactosidase enzyme. The MCS can be cleaved by different restriction enzymes so that the 
foreign DNA can be inserted within the lacZ α gene, thus disrupting the production of functional 
β-galactosidase. The chemical required for this screen is X-gal, a colourless modified galactose 
sugar that is metabolized by β-galactosidase to form 5-bromo-4-chloro-indoxyl which is 
spontaneously oxidized to the bright blue insoluble pigment 5, 5'-dibromo-4, 4'-dichloro-indigo 
thus functioning as an indicator. The hydrolysis of colourless X-gal by the β-galactosidase causes 
the characteristic blue colour in the colonies showing that the colonies are not transformed. 
White colonies indicate insertion of foreign DNA and loss of the cell’s ability to hydrolyze the 
marker. 
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11. Plasmid isolation 
 
1) Preparation of cell- 2ml of LB medium containing ampicillin was inoculated with a single 
colony of transformed (white) E.coli. The culture was incubated overnight at 37°C with vigorous 
shaking. 1.5 ml of culture was centrifuged at maximum speed for 30 sec at 4°C. Then the 
medium was removed by aspiration.  
 
2) Lysis of cell- Bacterial pellet was resuspended in 100µl of ice-cold Alkaline lysis solution I 
(50mM glucose, 25 mM Tris-Cl at pH 8 and 10mM EDTA at pH 8) by vigorous vortexing. Then 
200µl of freshly prepared Alkaline lysis solution II (0.2N NaOH and 1% SDS) was added to the 
suspension and mixed thoroughly. 150µl of ice-cold Alkaline lysis Solution III (5M potassium 
acetate, H2O and glacial acetic acid) was added and then the tube was kept on ice after mixing. 
Bacterial lysate was centrifuged at maximum speed for 5 min at 4°C and the supernatant was 
transferred to a fresh tube. 
  
2) Recovery of Plasmid- Nucleic acid was precipitated from the supernatant by adding 2 
volumes of ethanol at room temperature and vortexing for 2 min. Precipitated nucleic acid was 
collected by centrifugation at maximum speed for 5 min at 4°C. Supernatant was removed by 
gentle aspiration. 1ml of 70% ethanol was added to the pellet and mixed well. DNA was 
recovered by centrifugation at maximum speed for 2 min at 4°C. Again all supernatant was 
removed by aspiration. Tube was kept open for 5 min to evaporate all traces of ethanol. Nucleic 
acid was dissolved in 50µl of TE (pH 8.0) containing 20µg/ml DNase free RNase A and 
vortexed for few sec. DNA solution was stored at -20 °C.  
 
Then the insert, vector and the recombinant plasmid (obtained from white transformed 
colonies) were run on 2% agarose gel to check whether the vector ligated with insert (DNMT1) 
was incorporated successfully into the plasmid.  
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      RESULTS & DISCUSSION 
1. Results of in silico Sequence Analysis of DNMT1:  
The cDNA sequence of DNMT1 was retrieved (from Ensembl Genome Browser): 
Cytogenetic: 19p13.2 
cDNA size : 5351 bp 
ORF Size: 4851 bp (sequence in between the coloured regions) 
>ENST00000340748 cdna: KNOWN_protein_coding 
GGCTCCGTTCCATCCTTCTGCACAGGGTATCGCCTCTCTCCGTTTGGTACATCCCCTCCT 
CCCCCACGCCCGGACTGGGGTGGTAGACGCCGCCTCCGCTCATCGCCCCTCCCCATCGGT 
TTCCGCGCGAAAAGCCGGGGCGCCTGCGCTGCCGCCGCCGCGTCTGCTGAAGCCTCCGAG 
ATGCCGGCGCGTACCGCCCCAGCCCGGGTGCCCACACTGGCCGTCCCGGCCATCTCGCTG 
CCCGACGATGTCCGCAGGCGGCTCAAAGATTTGGAAAGAGACAGCTTAACAGAAAAGGAA 
TGTGTGAAGGAGAAATTGAATCTCTTGCACGAATTTCTGCAAACAGAAATAAAGAATCAG 
TTATGTGACTTGGAAACCAAATTACGTAAAGAAGAATTATCCGAGGAGGGCTACCTGGCT 
AAAGTCAAATCCCTTTTAAATAAAGATTTGTCCTTGGAGAACGGTGCTCATGCTTACAAC 
CGGGAAGTGAATGGACGTCTAGAAAACGGGAACCAAGCAAGAAGTGAAGCCCGTAGAGTG 
GGAATGGCAGATGCCAACAGCCCCCCCAAACCCCTTTCCAAACCTCGCACGCCCAGGAGG 
AGCAAGTCCGATGGAGAGGCTAAGCCTGAACCTTCACCTAGCCCCAGGATTACAAGGAAA 
AGCACCAGGCAAACCACCATCACATCTCATTTTGCAAAGGGCCCTGCCAAACGGAAACCT 
CAGGAAGAGTCTGAAAGAGCCAAATCGGATGAGTCCATCAAGGAAGAAGACAAAGACCAG 
GATGAGAAGAGACGTAGAGTTACATCCAGAGAACGAGTTGCTAGACCGCTTCCTGCAGAA 
GAACCTGAAAGAGCAAAATCAGGAACGCGCACTGAAAAGGAAGAAGAAAGAGATGAAAAA 
GAAGAAAAGAGACTCCGAAGTCAAACCAAAGAACCAACACCCAAACAGAAACTGAAGGAG 
GAGCCGGACAGAGAAGCCAGGGCAGGCGTGCAGGCTGACGAGGACGAAGATGGAGACGAG 
AAAGATGAGAAGAAGCACAGAAGTCAACCCAAAGATCTAGCTGCCAAACGGAGGCCCGAA 
GAAAAAGAACCTGAAAAAGTAAATCCACAGATTTCTGATGAAAAAGACGAGGATGAAAAG 
GAGGAGAAGAGACGCAAAACGACCCCCAAAGAACCAACGGAGAAAAAAATGGCTCGCGCC 
AAAACAGTCATGAACTCCAAGACCCACCCTCCCAAGTGCATTCAGTGCGGGCAGTACCTG 
GACGACCCTGACCTCAAATATGGGCAGCACCCACCAGACGCGGTGGATGAGCCACAGATG 
CTGACAAATGAGAAGCTGTCCATCTTTGATGCCAACGAGTCTGGCTTTGAGAGTTATGAG 
GCGCTTCCCCAGCACAAACTGACCTGCTTCAGTGTGTACTGTAAGCACGGTCACCTGTGT 
CCCATCGACACCGGCCTCATCGAGAAGAATATCGAACTCTTCTTTTCTGGTTCAGCAAAA 
CCAATCTATGATGATGACCCATCTCTTGAAGGTGGTGTTAATGGCAAAAATCTTGGCCCC 
ATAAATGAATGGTGGATCACTGGCTTTGATGGAGGTGAAAAGGCCCTCATCGGCTTCAGC 
ACCTCATTTGCCGAATACATTCTGATGGATCCCAGTCCCGAGTATGCGCCCATATTTGGG 
CTGATGCAGGAGAAGATCTACATCAGCAAGATTGTGGTGGAGTTCCTGCAGAGCAATTCC 
GACTCGACCTATGAGGACCTGATCAACAAGATCGAGACCACGGTTCCTCCTTCTGGCCTC 
AACTTGAACCGCTTCACAGAGGACTCCCTCCTGCGACACGCGCAGTTTGTGGTGGAGCAG 
GTGGAGAGTTATGACGAGGCCGGGGACAGTGATGAGCAGCCCATCTTCCTGACACCCTGC 
ATGCGGGACCTGATCAAGCTGGCTGGGGTCACGCTGGGACAGAGGCGAGCCCAGGCGAGG 
CGGCAGACCATCAGGCATTCTACCAGGGAGAAGGACAGGGGACCCACGAAAGCCACCACC 
ACCAAGCTGGTCTACCAGATCTTCGATACTTTCTTCGCAGAGCAAATTGAAAAGGATGAC 
AGAGAAGACAAGGAGAACGCCTTTAAGCGCCGGCGATGTGGCGTCTGTGAGGTGTGTCAG 
CAGCCTGAGTGTGGGAAATGTAAAGCCTGCAAGGACATGGTTAAATTTGGTGGCAGTGGA 
CGGAGCAAGCAGGCTTGCCAAGAGCGGAGGTGTCCCAATATGGCCATGAAGGAGGCAGAT 
GACGATGAGGAAGTCGATGATAACATCCCAGAGATGCCGTCACCCAAAAAAATGCACCAG 
GGGAAGAAGAAGAAACAGAACAAGAATCGCATCTCTTGGGTCGGAGAAGCCGTCAAGACT 
GATGGGAAGAAGAGTTACTATAAGAAGGTGTGCATTGATGCGGAAACCCTGGAAGTGGGG 
GACTGTGTCTCTGTTATTCCAGATGATTCCTCAAAACCGCTGTATCTAGCAAGGGTCACG 
30 
 
GCGCTGTGGGAGGACAGCAGCAACGGGCAGATGTTTCACGCCCACTGGTTCTGCGCTGGG 
ACAGACACAGTCCTCGGGGCCACGTCGGACCCTCTGGAGCTGTTCTTGGTGGATGAATGT 
GAGGACATGCAGCTTTCATATATCCACAGCAAAGTGAAAGTCATCTACAAAGCCCCCTCC 
GAAAACTGGGCCATGGAGGGAGGCATGGATCCCGAGTCCCTGCTGGAGGGGGACGACGGG 
AAGACCTACTTCTACCAGCTGTGGTATGATCAAGACTACGCGAGATTCGAGTCCCCTCCA 
AAAACCCAGCCAACAGAGGACAACAAGTTCAAATTCTGTGTGAGCTGTGCCCGTCTGGCT 
GAGATGAGGCAAAAAGAAATCCCCAGGGTCCTGGAGCAGCTCGAGGACCTGGATAGCCGG 
GTCCTCTACTACTCAGCCACCAAGAACGGCATCCTGTACCGAGTTGGTGATGGTGTGTAC 
CTGCCCCCTGAGGCCTTCACGTTCAACATCAAGCTGTCCAGTCCCGTGAAACGCCCACGG 
AAGGAGCCCGTGGATGAGGACCTGTACCCAGAGCACTACCGGAAATACTCCGACTACATC 
AAAGGCAGCAACCTGGATGCCCCTGAGCCCTACCGAATTGGCCGGATCAAAGAGATCTTC 
TGTCCCAAGAAGAGCAACGGCAGGCCCAATGAGACTGACATCAAAATCCGGGTCAACAAG 
TTCTACAGGCCTGAGAACACCCACAAGTCCACTCCAGCGAGCTACCACGCAGACATCAAC 
CTGCTCTACTGGAGCGACGAGGAGGCCGTGGTGGACTTCAAGGCTGTGCAGGGCCGCTGC 
ACCGTGGAGTATGGGGAGGACCTGCCCGAGTGCGTCCAGGTGTACTCCATGGGCGGCCCC 
AACCGCTTCTACTTCCTCGAGGCCTATAATGCAAAGAGCAAAAGCTTTGAAGATCCTCCC 
AACCATGCCCGTAGCCCTGGAAACAAAGGGAAGGGCAAGGGAAAAGGGAAGGGCAAGCCC 
AAGTCCCAAGCCTGTGAGCCGAGCGAGCCAGAGATAGAGATCAAGCTGCCCAAGCTGCGG 
ACCCTGGATGTGTTTTCTGGCTGCGGGGGGTTGTCGGAGGGATTCCACCAAGCAGGCATC 
TCTGACACGCTGTGGGCCATCGAGATGTGGGACCCTGCGGCCCAGGCGTTCCGGCTGAAC 
AACCCCGGCTCCACAGTGTTCACAGAGGACTGCAACATCCTGCTGAAGCTGGTCATGGCT 
GGGGAGACCACCAACTCCCGCGGCCAGCGGCTGCCCCAGAAGGGAGACGTGGAGATGCTG 
TGCGGCGGGCCGCCCTGCCAGGGCTTCAGCGGCATGAACCGCTTCAATTCGCGCACCTAC 
TCCAAGTTCAAAAACTCTCTGGTGGTTTCCTTCCTCAGCTACTGCGACTACTACCGGCCC 
CGGTTCTTCCTCCTGGAGAATGTCAGGAACTTTGTCTCCTTCAAGCGCTCCATGGTCCTG 
AAGCTCACCCTCCGCTGCCTGGTCCGCATGGGCTATCAGTGCACCTTCGGCGTGCTGCAG 
GCCGGTCAGTACGGCGTGGCCCAGACTAGGAGGCGGGCCATCATCCTGGCCGCGGCCCCT 
GGAGAGAAGCTCCCTCTGTTCCCGGAGCCACTGCACGTGTTTGCTCCCCGGGCCTGCCAG 
CTGAGCGTGGTGGTGGATGACAAGAAGTTTGTGAGCAACATAACCAGGTTGAGCTCGGGT 
CCTTTCCGGACCATCACGGTGCGAGACACGATGTCCGACCTGCCGGAGGTGCGGAATGGA 
GCCTCGGCACTGGAGATCTCCTACAACGGGGAGCCTCAGTCCTGGTTCCAGAGGCAGCTC 
CGGGGCGCACAGTACCAGCCCATCCTCAGGGACCACATCTGTAAGGACATGAGTGCATTG 
GTGGCTGCCCGCATGCGGCACATCCCCTTGGCCCCAGGGTCAGACTGGCGCGATCTGCCC 
AACATCGAGGTGCGGCTCTCAGACGGCACCATGGCCAGGAAGCTGCGGTATACCCACCAT 
GACAGGAAGAACGGCCGCAGCAGCTCTGGGGCCCTCCGTGGGGTCTGCTCCTGCGTGGAA 
GCCGGCAAAGCCTGCGACCCCGCAGCCAGGCAGTTCAACACCCTCATCCCCTGGTGCCTG 
CCCCACACCGGGAACCGGCACAACCACTGGGCTGGCCTCTATGGAAGGCTCGAGTGGGAC 
GGCTTCTTCAGCACAACCGTCACCAACCCCGAGCCCATGGGCAAGCAGGGCCGCGTGCTC 
CACCCAGAGCAGCACCGTGTGGTGAGCGTGCGGGAGTGTGCCCGCTCCCAGGGCTTCCCT 
GACACCTACCGGCTCTTCGGCAACATCCTGGACAAGCACCGGCAGGTGGGCAATGCCGTG 
CCACCGCCCCTGGCCAAAGCCATTGGCTTGGAGATCAAGCTTTGTATGTTGGCCAAAGCC 
CGAGAGAGTGCCTCAGCTAAAATAAAGGAGGAGGAAGCTGCTAAGGACTAGTTCTGCCCT 
CCCGTCACCCCTGTTTCTGGCACCAGGAATCCCCAACATGCACTGATGTTGTGTTTTTAA 
CATGTCAATCTGTCCGTTCACATGTGTGGTACATGGTGTTTGTGGCCTTGGCTGACATGA 
AGCTGTTGTGTGAGGTTCGCTTATCAACTAATGATTTAGTGATCAAATTGTGCAGTACTT 
TGTGCATTCTGGATTTTAAAAGTTTTTTATTATGCATTATATCAAATCTACCACTGTATG 
AGTGGAAATTAAGACTTTATGTAGTTTTTATATGTTGTAATATTTCTTCAAATAAATCTC 
TCCTATAAACC 
 
 
Primer designed- 
 
Forward primer: ATGCCGGCGCGTACCGCC 
Reverse primer: CTCCTTCGACGATTCCTGATCA 
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P26358 Human DNMT1 (1616aa) 
MPARTAPARVPTLAVPAISLPDDVRRRLKDLERDSLTEKECVKEKLNLLHEFLQTEIKNQLCDLETKLRK 
EELSEEGYLAKVKSLLNKDLSLENGAHAYNREVNGRLENGNQARSEARRVGMADANSPPKPLSKPRTPRR 
SKSDGEAKPEPSPSPRITRKSTRQTTITSHFAKGPAKRKPQEESERAKSDESIKEEDKDQDEKRRRVTSR 
ERVARPLPAEEPERAKSGTRTEKEEERDEKEEKRLRSQTKEPTPKQKLKEEPDREARAGVQADEDEDGDE 
KDEKKHRSQPKDLAAKRRPEEKEPEKVNPQISDEKDEDEKEEKRRKTTPKEPTEKKMARAKTVMNSKTHP 
PKCIQCGQYLDDPDLKYGQHPPDAVDEPQMLTNEKLSIFDANESGFESYEALPQHKLTCFSVYCKHGHLC 
PIDTGLIEKNIELFFSGSAKPIYDDDPSLEGGVNGKNLGPINEWWITGFDGGEKALIGFSTSFAEYILMD 
PSPEYAPIFGLMQEKIYISKIVVEFLQSNSDSTYEDLINKIETTVPPSGLNLNRFTEDSLLRHAQFVVEQ 
VESYDEAGDSDEQPIFLTPCMRDLIKLAGVTLGQRRAQARRQTIRHSTREKDRGPTKATTTKLVYQIFDT 
FFAEQIEKDDREDKENAFKRRRCGVCEVCQQPECGKCKACKDMVKFGGSGRSKQACQERRCPNMAMKEAD 
DDEEVDDNIPEMPSPKKMHQGKKKKQNKNRISWVGEAVKTDGKKSYYKKVCIDAETLEVGDCVSVIPDDS 
SKPLYLARVTALWEDSSNGQMFHAHWFCAGTDTVLGATSDPLELFLVDECEDMQLSYIHSKVKVIYKAPS 
ENWAMEGGMDPESLLEGDDGKTYFYQLWYDQDYARFESPPKTQPTEDNKFKFCVSCARLAEMRQKEIPRV 
LEQLEDLDSRVLYYSATKNGILYRVGDGVYLPPEAFTFNIKLSSPVKRPRKEPVDEDLYPEHYRKYSDYI 
KGSNLDAPEPYRIGRIKEIFCPKKSNGRPNETDIKIRVNKFYRPENTHKSTPASYHADINLLYWSDEEAV 
VDFKAVQGRCTVEYGEDLPECVQVYSMGGPNRFYFLEAYNAKSKSFEDPPNHARSPGNKGKGKGKGKGKP 
KSQACEPSEPEIEIKLPKLRTLDVFSGCGGLSEGFHQAGISDTLWAIEMWDPAAQAFRLNNPGSTVFTED 
CNILLKLVMAGETTNSRGQRLPQKGDVEMLCGGPPCQGFSGMNRFNSRTYSKFKNSLVVSFLSYCDYYRP 
RFFLLENVRNFVSFKRSMVLKLTLRCLVRMGYQCTFGVLQAGQYGVAQTRRRAIILAAAPGEKLPLFPEP 
LHVFAPRACQLSVVVDDKKFVSNITRLSSGPFRTITVRDTMSDLPEVRNGASALEISYNGEPQSWFQRQL 
RGAQYQPILRDHICKDMSALVAARMRHIPLAPGSDWRDLPNIEVRLSDGTMARKLRYTHHDRKNGRSSSG 
ALRGVCSCVEAGKACDPAARQFNTLIPWCLPHTGNRHNHWAGLYGRLEWDGFFSTTVTNPEPMGKQGRVL 
HPEQHRVVSVRECARSQGFPDTYRLFGNILDKHRQVGNAVPPPLAKAIGLEIKLCMLAKARESASAKIKE 
EEAAKD 
 
 
 
2. Isolation of RNA from Blood: 
  RNA was extracted from normal human blood and the concentration was determined by the 
Nanodrop to be 188.8 µg/ml and purity was 1.89 (OD 260/280). Hence the isolated RNA was very much 
pure and could be used further for cDNA synthesis. 
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3. PCR Amplification of DNMT1 gene: 
The gene specific PCR amplification of DNMT1 gave the following result after 
electrophoresis on 0.8% agarose gel showing that the cDNA of DNMT1 gene is approximately 
6000 bp in length.  
 
                                   
 
                           Fig.13.   DNMT1 gene after amplification  
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 4. Transformation and Cloning: 
         The recombinant vector pBSK(-) containing the amplified DNMT1 gene transformed into 
E.coli cells when subsequently cultured, formed white colonies in the blue white colony 
screening (Fig. 14). The agarose gel electrophoresis of the recombinant plasmid (obtained from 
white transformed colonies) provides evidence for successful cloning of DNMT1 gene (Fig. 15). 
 
                     
 
                       
 
                 Fig.14. White colonies formed by transformed cells in blue white colony screening 
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Fig.15. Clone checking by electrophoresis of insert, vector and the recombinant plasmid 
(obtained   from white transformed colonies) 
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        CONCLUSION 
 
The present study was carried out to clone and characterize the DNMT1 gene. The gene 
was successfully cloned and further studies will be required to fully comprehend the structural 
and mechanistic complexities of the maintenance methyltransferase DNMT1. Cloning increase 
the opportunity and stock for research related to normal function and modulation of its own 
function as well as modulation of others by this protein, in addition it will help to understand the 
structural relationship and drug development against specific function. Hence our next aim is to 
over express the DNMT1 in suitable vectors and purification of the protein. Extent upto which 
DNMT1 is involved in cancer development will be better understood after developing large 
number of expression vectors or cells.  
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